Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2020 Sep 27;21(19):7118.
doi: 10.3390/ijms21197118.

Paediatric Formulation: Design and Development

Antonio Lopalco  1 , Nunzio Denora  1
Affiliations
Editorial

Paediatric Formulation: Design and Development

Antonio Lopalco et al. Int J Mol Sci. .

Abstract

The development of medicines designed for children can be challenging since this distinct patient population requires specific needs. A formulation designed for paediatric patients must consider the following aspects: patient population variability; dose flexibility; route of administration; patient compliance; drug and excipient tolerability. The purpose of this Special Issue entitled "Paediatric Formulation: Design and Development" is to provide an update on both state-of-the-art methodology and operational challenges in the design and development of paediatric formulations. It aims at re-evaluating what is needed for more progress in the design and development of age-appropriate treatments for paediatric diseases, focusing on: formulation development; drug delivery design; efficacy, safety, and tolerability of drugs and excipients. This editorial, briefly, summarizes the objects of nine original research and review papers published in this Special Issue.

Keywords: acceptable; age-related; children; design; development; excipient; formulation; paediatric; palatable; taste-masking.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

References

    1. Allen L.V. Dosage form design and development. Clin. Ther. 2008;30:2102–2111. doi: 10.1016/j.clinthera.2008.11.015. - DOI - PubMed
    1. Lopalco A., Denora N., Laquintana V., Cutrignelli A., Franco M., Robota M., Hauschildt N., Mondelli F., Arduino I., Lopedota A. Taste masking of propranolol hydrochloride by microbeads of EUDRAGIT® E PO obtained with prilling technique for paediatric oral administration. Int. J. Pharm. 2020;574:118922. doi: 10.1016/j.ijpharm.2019.118922. - DOI - PubMed
    1. Laquintana V., Asim M.H., Lopedota A., Cutrignelli A., Lopalco A., Franco M., Bernkop-Schnürch A., Denora N. Thiolated hydroxypropyl-β-cyclodextrin as mucoadhesive excipient for oral delivery of budesonide in liquid paediatric formulation. Int. J. Pharm. 2019;572:118820. doi: 10.1016/j.ijpharm.2019.118820. - DOI - PubMed
    1. Lopalco A., Curci A., Lopedota A., Cutrignelli A., Laquintana V., Franco M., Denora N. Pharmaceutical preformulation studies and paediatric oral formulations of sodium dichloroacetate. Eur. J. Pharm. Sci. 2019;127:339–350. doi: 10.1016/j.ejps.2018.11.013. - DOI - PubMed
    1. Kearns G.L., Abdel-Rahman S.M., Alander S.W., Blowey D.L., Leeder J.S., Kauffman R.E. Developmental pharmacology—Drug disposition, action and therapy in infants and children. N. Engl. J. Med. 2003;349:1157–1167. doi: 10.1056/NEJMra035092. - DOI - PubMed

Publication types

LinkOut - more resources